Evidence map›Paper›PMID 35150571›Full record

ArticleThe Journal of infectious diseases2022

Detection and Kinetics of Subgenomic Severe Acute Respiratory Syndrome Coronavirus 2 RNA Viral Load in Longitudinal Diagnostic RNA-Positive Samples.

Meagan E Deming, Tracy Q Dong, Vaidehi Agrawal, Margaret G Mills, Meei Li W Huang, Alexander L Greninger, Keith R Jerome, Mark H Wener, Michael K Paasche-Orlow, Patricia Kissinger and 12 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 1 country.

Meagan E DemingThe Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-2574-0542
Tracy Q DongVaccine and Infectious Disease Division, Fred Hutchinson, Cancer Research Center, Seattle, Washington, USA.
Vaidehi AgrawalThe Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Margaret G MillsDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Meei Li W HuangDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Alexander L GreningerVaccine and Infectious Disease Division, Fred Hutchinson, Cancer Research Center, Seattle, Washington, USA.
Keith R JeromeVaccine and Infectious Disease Division, Fred Hutchinson, Cancer Research Center, Seattle, Washington, USA.
Mark H WenerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Michael K Paasche-OrlowSection of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
Patricia KissingerDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine.
Alfred LukSection of Infectious Diseases, John W. Deming, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Risa M HoffmanDivision of Infectious Diseases, David Geffen School of Medicine at the University of California, Los Angeles, California, USA.
Jenell StewartDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Angelica C KottkampDepartment of Population Health; New York University, Grossman School of Medicine, New York, New York, USA.
Anna BershteynDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.
Helen Y ChuDivision of Infectious Diseases & Immunology, Department of Medicine, New York University Grossman, School of Medicine, New York, New York, USA.
Helen C Stankiewicz KaritaPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Christine M JohnstonVaccine and Infectious Disease Division, Fred Hutchinson, Cancer Research Center, Seattle, Washington, USA.
Anna WaldVaccine and Infectious Disease Division, Fred Hutchinson, Cancer Research Center, Seattle, Washington, USA.
Ruanne BarnabasDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Elizabeth R BrownVaccine and Infectious Disease Division, Fred Hutchinson, Cancer Research Center, Seattle, Washington, USA.
Kathleen M NeuzilThe Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
University of Washington · USFred Hutch Cancer Center · USUniversity of Maryland, Baltimore · USTulane University · USBoston University · USNew York University · USUniversity of California, Los Angeles · US

Funding

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2M
FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGYT32AI007524 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1997 to 2026
$6.4M
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA TrialR01CA213130 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MADELEINE, MARGARET M, WALD, ANNA · 2017 to 2022
$4.6M
Gates Foundation INV-016204NCI NIH HHS R01 CA213130NIAID NIH HHS T32 AI007524NIAID NIH HHS UM1 AI148684
6 · The paper itself

Abstract

While detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by diagnostic reverse-transcription polymerase chain reaction (RT-PCR) is highly sensitive for viral RNA, the nucleic acid amplification of subgenomic RNAs (sgRNAs) that are the product of viral replication may more accurately identify replication. We characterized the diagnostic RNA and sgRNA detection by RT-PCR from nasal swab samples collected daily by participants in postexposure prophylaxis or treatment studies for SARS-CoV-2. Among 1932 RT-PCR-positive swab samples with sgRNA tests, 40% (767) had detectable sgRNA. Above a diagnostic RNA viral load (VL) threshold of 5.1 log10 copies/mL, 96% of samples had detectable sgRNA with VLs that followed a linear trend. The trajectories of diagnostic RNA and sgRNA VLs differed, with 80% peaking on the same day but duration of sgRNA detection being shorter (8 vs 14 days). With a large sample of daily swab samples we provide comparative sgRNA kinetics and a diagnostic RNA threshold that correlates with replicating virus independent of symptoms or duration of illness.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingHumansKineticsRNA, ViralViral LoadRNA, ViralCOVID-19detectionkineticsSARS-CoV-2subgenomic RNAviral load

Identifiers

PMID35150571
PMCPMC8903395
OpenAlexW4210868151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.